Literature DB >> 25940989

Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.

Pi-Yueh Chang1,2,3, Cheng-Tao Yang4, Ching-Hui Cheng1,2, Kuang-Hui Yu5,6.   

Abstract

AIM: To compare the diagnostic performance of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) in the diagnosis of patients with rheumatoid arthritis (RA) in Taiwan.
METHODS: Serum concentrations of RF and anti-CCP were measured in 246 cases, including 39 patients with RA and 207 patients with other rheumatic diseases (non-RA). The age, sex, clinical presentation, RF, anti-CCP results and the final diagnoses were recorded and analyzed. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative likelihood ratio (LR-) were calculated.
RESULTS: Among all 246 patients, 39 (15.9%) were diagnosed with RA and 207 (84.1%) were diagnosed with other rheumatic diseases (non-RA). In the diagnosis of RA, the sensitivity, specificity, PPV, NPV, LR+ and LR- of the RF test were 67%, 79%, 37%, 93%, 3.12, and 0.42, respectively. The corresponding data for the anti-CCP test were 79%, 98%, 86%, 96%, 32.91 and 0.21, respectively. The presence of either anti-CCP or RF increased the sensitivity to 85%, and when they both were present, the specificity increased to 98%. Among the 39 RA patients, 26 (66.7%) tested positive for RF, and 31 (79.5%) tested positive for anti-CCP. RF was positive in two of eight anti-CCP-negative patients with RA, and anti-CCP was positive in seven of 13 RF-negative patients with RA.
CONCLUSIONS: The RF and anti-CCP tests are complementary, and the co-detection of these antibodies can increase the detection rate and provide important clinical value in the diagnosis of RA. Both anti-CCP and RF positivity are useful for the diagnosis of RA, and use of both tests together improves the diagnostic sensitivity.
© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  anti-cyclic citrullinated peptide; likelihood ratio; predictive value; rheumatoid arthritis; rheumatoid factor; sensitivity

Mesh:

Substances:

Year:  2015        PMID: 25940989     DOI: 10.1111/1756-185X.12552

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  6 in total

1.  Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance.

Authors:  Karthikeyan P Iyengar; Abhishek Vaish; Arvind Nune
Journal:  J Clin Orthop Trauma       Date:  2021-12-01

2.  Assessment of Serum Lipid Profiles and High-sensitivity C-reactive Protein Among Patients Suffering from Rheumatoid Arthritis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study.

Authors:  Gashaw Dessie; Yewondwossen Tadesse; Birhanu Demelash; Solomon Genet
Journal:  Open Access Rheumatol       Date:  2020-09-23

3.  Computed tomography of pulmonary changes in rheumatoid arthritis: carcinoembryonic antigen (CEA) as a marker of airway disease.

Authors:  Milene Caroline Koch; Ivânio Alves Pereira; Luiz Felipe Souza Nobre; Fabricio Souza Neves
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

Review 4.  Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis.

Authors:  Qinghua Fang; Jiaxin Ou; Kutty Selva Nandakumar
Journal:  Mediators Inflamm       Date:  2019-10-27       Impact factor: 4.711

5.  Prevalence and relevant factors of positive RF in brucellosis patients with arthralgia.

Authors:  Siwen Zhang; Jing Hu; Shuqi An; Mujinyan Li; Fande Li; Peng Zhang; Xiangyi Zhang; Huixin Yang; Taijun Wang; Jingjing Luo; Fangfang Hu; Jiashuo Liu; Qing Zhen
Journal:  PLoS Negl Trop Dis       Date:  2021-09-20

6.  Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database.

Authors:  Chien-Hsueh Tung; Ning-Sheng Lai; Chung-Yi Li; Shiang-Jiun Tsai; Yen-Chun Chen; Yi-Chun Chen
Journal:  BMJ Open       Date:  2018-07-23       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.